Applied Therapeutics Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the presentation of data at the American Heart Association (AHA) Scientific Sessions 2019 in Philadelphia (November 16-18, 2019) on AT-001, a novel, potent and selective aldose reductase inhibitor (ARI) in Phase 3 clinical development for Diabetic Cardiomyopathy (DbCM).
“We are pleased to present additional data at AHA supporting our clinical rationale for development of AT-001 in Diabetic Cardiomyopathy, a fast-moving form of heart failure for which no treatments exist,” said Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics. “Reduction in NTproBNP – an important cardiac stress biomarker shown to correlate with long term heart failure outcomes – is a strong preliminary indicator of efficacy in this patient population. Our ongoing Phase 3 study, ARISE-HF, represents an important step forward for patients as the first pivotal study to date in DbCM.”
Clinical Assessment of AT-001, an Aldose Reductase Inhihibitor in Development for Diabetic Cardiomyopathy: a 28 day proof of concept study
(poster presentation Monday, Nov 18, from 1:30-2:00pm)
AT-001 selectivity and affinity for AR has resulted in potent AR inhibition within a favorable safe dosing range
Observed reductions NT-proBNP, a validated cardiac stress biomarker, over 28 days of treatment with AT-001 support further investigation of the therapeutic potential of this novel agent in subjects with DbCM